Palabras clave
Sistema inmunitario
Inhibidor de la tirosina quinasa
Suspensión del tratamiento
Cómo citar
Copyright © | Todos los derechos reservados.
La revista posee los derechos de autor exclusivos para la publicación de este artículo en los términos de la ley brasileña 9610/98.
Reproducción parcial
El uso de partes de los textos, figuras y cuestionario del artículo es libre, siendo obligatoria la citación de los autores y revista.
Reproducción total
Está expresamente prohibido y debe ser autorizado por la revista.
Resumen
Objetivo: Realizar un análisis y revisión de los principales artículos disponibles sobre la influencia del sistema inmune en el éxito de la descontinuación de los inhibidores de tirosina quinasa en la leucemia mieloide crónica. Revisión bibliográfica: El concepto reciente de remisión libre de tratamiento (RLT) surge como un objetivo atractivo, permitiendo que pacientes diagnosticados con leucemia mieloide crónica y con respuestas moleculares profundas pueden descontinuar el tratamiento con los inhibidores de tirosina quinasa (ITQ). El sistema inmune desempeña un papel fundamental en el éxito de la descontinuación de los ITQ. Las células natural killers (NK) y las células T CD8+ efectoras son esenciales para la vigilancia inmunológica y el control de la enfermedad. Además, la presencia de células T citotóxicas específicas está asociada con una remisión sostenida. Adicionalmente, el tratamiento con ITQ reduce la carga leucémica, permitiendo la reactivación de las respuestas inmunológicas efectivas y la eliminación de las células tumorales. Consideraciones finales: En este contexto, existe la necesidad de nuevos enfoques terapéuticos que refuercen la respuesta inmune y exploren combinaciones de ITQ con agentes inmunoestimulantes, con el objetivo de optimizar el mantenimiento de la remisión y brindar una terapia más efectiva que mejore la calidad de vida.
Referencias
ABRUZZESE E, et al. Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence, and recommendations. Therapeutic Advances in Hematology, 2020; 11.
AHMAD SM, et al. The stimulation of PD-L1-specific cytotoxic T lymphocytes can both directly and indirectly enhance antileukemic immunity. Blood Cancer Journal, 2014; 4(7): e230.
ATALLAH E, SCHIFFER CA. Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom? Haematologica, 2020; 105(12): 2738–2745.
BOSI GR. Leucemia mieloide crônica: expansão de células natural killer de pacientes refratários ou intolerantes aos inibidores de tirosino quinase. Ufrgs.br, 2017.
BURCHERT A, et al. Sustained Molecular Response With Interferon Alfa Maintenance After Induction Therapy With Imatinib Plus Interferon Alfa in Patients With Chronic Myeloid Leukemia. Journal of Clinical Oncology, 2010; 28(8): 1429–1435.
CARULLI G, et al. Abnormal phenotype of bone marrow plasma cells in patients with chronic myeloid leukemia undergoing therapy with Imatinib. Leukemia research, 2010; 34(10): 1336-1339.
CHEN CIU, et al. Development and dynamics of robust T-cell responses to CML under imatinib treatment. Blood, 2008, 111(11): 5342–5349.
DEEPTHI BODDU, et al. Effect of imatinib on growth in children with chronic myeloid leukemia. Pediatric Hematology and Oncology, 2019; 36(4): 189–197.
DE LAVALLADE H, et al. Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling. Blood, 2013; 122(2): 227–238.
GERLONI M, ZANETTI M. CD4 T cells in tumor immunity. In: Springer seminars in immunopathology. Springer-Verlag, 2005; 37-48.
HSIEH YC, et al. Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape. Leukemia, 2021; 35(5): 1229–1242.
HUGHES A, et al. CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors. Blood, 2017; 129(9): 1166-1176.
ILANDER M, et al. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia, 2017; 31(5): 1108.
INZOLI E, et al. Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success. American Journal of Hematology, 2022; 97(8): 1075–1085.
IRIYAMA N, et al. Enhanced perforin expression associated with dasatinib therapy in natural killer cells. Leukemia research, 2018; 68: 1-8.
KUMAGAI T, et al. Silent NK/T cell reactions to dasatinib during sustained deep molecular response before cessation are associated with longer treatment‐free remission. Cancer Science, 2020; 111(8): 2923–2934.
LEE J, et al. Epigenetic modification and antibody-dependent expansion of memory-like NK cells in human cytomegalovirus-infected individuals. Immunity, 2015; 42(3): 431-442.
LOPEZ-VERGÈS S, et al. CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood, 2010; 116(19): 3865–3874.
MATSUSHITA M, et al. Monitoring of immunity against leukemia stem cell in CML patients after cessation of TKI. Journal for Immunotherapy of Cancer, 2015; 3: S2.
MINCIACCHI VR, et al. Chronic Myeloid Leukemia: A Model Disease of the Past, Present and Future. Cells, 2021; 10(1): 117.
MIZOGUCHI I, et al. Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib. Cancer Science, 2013; 104(9): 1146–1153.
MOHAMAD MOHTY, et al. Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia. Blood, 2004; 103(12): 4666–4668.
MUSTJOKI S, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia, 2009; 23(8): 1398-1405.
NAGATA Y, et al. Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion. International journal of hematology, 2010; 91(5): 799-807.
NIELSEN CM, et al. Functional Significance of CD57 Expression on Human NK Cells and Relevance to Disease. Frontiers in Immunology, 2013; 4.
OHYASHIKI K, et al. Increased natural killer cells and decreased CD3+ CD8+ CD62L+ T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib. British journal of hematology, 2012; 157(2): 254-256.
PORKKA K, et al. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer: Interdisciplinary International Journal of the American Cancer Society, 2010; 116(2): 377-386.
REA D, et al. Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study. Hematological, 2017; 102(8): 1368–1377.
REZVANI K, et al. Engineering Natural Killer Cells for Cancer Immunotherapy. Molecular Therapy, 2017; 25(8): 1769–1781.
ROMEE R, et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Science translational medicine, 2016.
ROSS, DM, et al. Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia. British journal of haematology, 2019; 186(3): e56-e60.
RUGGIU M, et al. Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia. Leukemia and lymphoma, 2017; 59(7): 1659–1665.
RUSAKIEWICZ S, et al. BCR/ABL-specific CD8+ T cells can be detected from CML patients, but are only expanded from healthy donors. Cancer immunology, immunotherapy, 2009; 58(9): 1449-1457.
SALIH J, et al. The BCR/ABL‐inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity. International Journal of cancer, 2010; 127(9): 2119-2128.
SCHADE AE, et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood, 2008; 111(3): 1366-1377.
TAKAHASHI N, et al. Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica, 2011; 97(6): 903–906.
WANG H, et al. Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance. Blood, 2005; 105(3): 1135–1143.
WEICHSEL R, et al. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clinical Cancer Research, 2008; v. 14; n. 8; p. 2484-2491.
YUHO NAJIMA, et al. Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response - The final results of the D-first study. Leukemia Research, 2018; 66: 66–72.
ZHANG Z, et al. Exploration of treatment‐free remission in CML, based on molecular monitoring. Cancer Medicine, 2023; 13: 1.